Xandro

Xandro sells microbiome-focused dietary supplements and at-home gut-health test kits. Single-month supplement bundles run $55–$75, placing the line in the mid-range; the 3-month “Total Reset” kit plus two gut tests sells for about $249. Everything is ordered direct-to-consumer through xandrolab.com; no retail distribution is listed. The company formulates around sequenced probiotic strains plus spore-based prebiotics that are matched to individual microbiome results. Customers receive a prepaid stool-sample kit, an online dashboard that maps 30+ microbial markers, and personalized refill packs that adjust strain ratios each quarter. This test-and-replenish loop is marketed as “precision probiotics,” a positioning reinforced by published third-party sequencing methods. Core buyers are 25-45-year-old urban professionals who already track sleep, macros, or fitness metrics and want data-driven digestion solutions. The brand speaks in bio-hacking language—optimization, resilience, “gut-brain KPIs”—and stresses transparent lab reports over broad “wellness” claims, appealing to values of scientific self-experimentation and measurable progress. Xandro competes with both mass-market probiotic pills and venture-backed microbiome testing startups. It differentiates by bundling sequencing, algorithmic strain selection, and ongoing supplement fulfillment into one vertically integrated subscription, eliminating the need for customers to reconcile separate test results and off-the-shelf bottles.